Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SI | P14410 | 2/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7344628 | 0.82 | NUDT1 (0.41) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL5695130 | 0.80 | CYP2E1 (0.39) | MGAMGAASIMGAM2KDM4E | |
| SCHEMBL3963475 | 0.79 | ALDH1A1 (0.40) | HTTDHODHPARP1ALDH1A1 | |
| SCHEMBL3962137 | 0.78 | DHODH (0.43) | HTTDHODHPARP1ALDH1A1 | |
| SCHEMBL1285685 | 0.78 | CACNA1H (0.46) | HTTDHODHKDM4EDYRK1A | |
| SCHEMBL15780565 | 0.77 | DHODH (0.51) | HTTDHODHPARP1ALDH1A1 | |
| SCHEMBL643678 | 0.77 | DHODH (0.64) | DHODHGAAKDM4EALDH1A1 | |
| SCHEMBL29893957 | 0.77 | DHODH (0.64) | DHODHGAAKDM4EALDH1A1 | |
| SCHEMBL10146528 | 0.76 | PARP1 (0.56) | HTTDHODHPARP1GAAHSD17B10 | |
| SCHEMBL20509760 | 0.76 | PARP1 (0.66) | PARP1GAAKDM4ELMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022135365-A1 | DISUBSTITUTED CYCLOPENTANE KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-30 | — | — | WO | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | HTT 1560/4885DHODH 2233/4885PARP1 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.